

NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit

January 4, 2022

ERRATA

Appeal No. 21-1070

NOVARTIS PHARMACEUTICALS CORPORATION,
Plaintiff-Appellee

v.

**ACCORD HEALTHCARE, INC., AUROBINDO
PHARMA LTD., AUROBINDO PHARMA USA, INC.,
DR. REDDY'S LABORATORIES, INC., DR. REDDY'S
LABORATORIES, LTD., EMCURE
PHARMACEUTICALS LTD., HERITAGE
PHARMACEUTICALS INC., GLENMARK
PHARMACEUTICALS INC., USA, GLENMARK
PHARMACEUTICALS LIMITED, HETERO USA,
INC., HETERO LABS LIMITED UNIT-V, HETERO
LABS LIMITED, MYLAN PHARMACEUTICALS,
INC., PRINSTON PHARMACEUTICAL INC.,
STRIDES GLOBAL PHARMA PRIVATE LIMITED,
STRIDES PHARMA, INC., TORRENT PHARMA
INC., TORRENT PHARMACEUTICALS LTD.,
ZYDUS PHARMACEUTICALS (USA) INC., CADILA
HEALTHCARE LTD., APOTEX INC., APOTEX
CORP., SUN PHARMACEUTICAL INDUSTRIES,
LTD., SUN PHARMACEUTICAL INDUSTRIES INC.,**

2 NOVARTIS PHARMACEUTICALS v. ACCORD HEALTHCARE INC.

SUN PHARMA GLOBAL FZE,
Defendants

HEC PHARM CO., LTD., HEC PHARM USA INC.,
Defendants-Appellants

Decided: January 3, 2022
Precedential opinion

Please make the following change:

Page 2, line 7 (majority opinion): the issuance date of
“January 3, 2021” is changed to “January 3, 2022”.